Introduction: Hypermutable Pseudomonas aeruginosa (HYPa)strains are frequently associated with chronic respiratory infections in patients with cystic fibrosis leading to increased morbidity and mortality. HYPa have increased mutation rates resulting in multidrug-resistance and treatment failure. Aims: To evaluate bacterial killing and resistance suppression of clinically relevant meropenem (MER) and tobramycin (TOB) dosage regimens against two clinical […]
akosuaadom
- Monash Institute of Pharmaceutical Sciences, Parkville, Victoria